I think you did answer my question or my concern.
Another problem with the CDR that we were made aware of in previous testimony was that rare diseases were getting the short end of the stick in the drug review process, with the vast majority often not passing through the CDR, which caters to more widely used drugs. In terms of drugs that are used for rare forms of cancer per se, how has the JODR been dealing with those?
We've heard a bit about that today, but I'm particularly interested in this area of rare diseases.